Immunology · Rare DiseaseTrial Updateclinicalmid-term

Plerixafor vs G-CSF Trial for WHIM Syndrome: A Comparative Study

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 12:31:53 AM

Assessment confidence: 92% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial comparing plerixafor to G-CSF for WHIM syndrome could significantly alter treatment paradigms in this rare disease space. A successful outcome may lead to increased competition and necessitate strategic shifts for companies involved in rare disease therapies. Regulatory context from FDA (FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)) supports the near-term read. Assessment grounded in 8 ranked evidence items (8 high-relevance).

Strategic Assessment

If successful, plerixafor may expand treatment options for WHIM syndrome, necessitating strategic adjustments for companies involved in rare disease therapies. The strongest clinical anchor is Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome (ClinicalTrials.gov), sub-indication match (rare disease); entity match (plerixafor). In rare disease, 7 regulatory and 0 competitive items passed relevance filtering for Plerixafor.

Competitive Pressure

The most relevant competitive pressure comes from This trial could position plerixafor as a potential alternative treatment for WHIM syndrome, impacting G-CSF's market share in this niche..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG) (FDA). Sub-indication match (rare disease); Regulatory pathway relevance (nda). The trial results could influence future regulatory approvals and labeling for plerixafor, potentially expanding its use in rare disease indications.

Key Risks

Elevated medium regulatory exposure for Plerixafor could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If plerixafor proves effective, it could capture market share from G-CSF, impacting revenue streams for companies currently reliant on G-CSF for WHIM syndrome treatment.
If successful, plerixafor may expand treatment options for WHIM syndrome, necessitating strategic adjustments for companies involved in rare disease therapies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and patient outcomes at the end of year 1 and year 2 evaluations.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
ClinicalTrials.govhigh relevance
Sub-indication match (rare disease); Entity match (plerixafor)
FDA document
View source
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoi
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
MeDe Study: Comparing Median Nerve Decompression at the Carpal Tunnel Alone Versus Median Nerve Decompression at Both the Carpal Tunnel and Lacertus Fibrosis in Adults With Carpal Tunnel Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With Liver Disease Called NASH/MASH Who Have Cirrhosis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Plerixafor
G-CSF
NIAID
WHIM Syndrome patients

Commercial impact

medium

If plerixafor proves effective, it could capture market share from G-CSF, impacting revenue streams for companies currently reliant on G-CSF for WHIM syndrome treatment.

Regulatory impact

medium

The trial results could influence future regulatory approvals and labeling for plerixafor, potentially expanding its use in rare disease indications.

What to watch

Monitor trial results and patient outcomes at the end of year 1 and year 2 evaluations.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.